-
公开(公告)号：US20230120254A1
公开(公告)日：2023-04-20
申请号：US17932151
申请日：2022-09-14
申请人： Pfizer Inc.
发明人： Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC分类号： A61K31/403 , A61P31/14 , A61K31/427 , C07D403/12 , A61K31/401
摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号：US20220062232A1
公开(公告)日：2022-03-03
申请号：US17395139
申请日：2021-08-05
申请人： Pfizer Inc.
发明人： Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC分类号： A61K31/403 , C07D403/12 , A61K31/427 , A61P31/14
摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号：US20230019853A1
公开(公告)日：2023-01-19
申请号：US17341877
申请日：2021-06-08
申请人： Pfizer Inc.
发明人： Christopher Ryan Butler , Michelle Renee Garnsey , Kevin Alexander Ogilvie , Jana Polivkova , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC分类号： C07D471/20 , C07D519/00
摘要： Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
-
公开(公告)号：US11452711B2
公开(公告)日：2022-09-27
申请号：US17660270
申请日：2022-04-22
申请人： Pfizer Inc.
发明人： Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC分类号： C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427 , A61K31/401
摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号：US20220017548A1
公开(公告)日：2022-01-20
申请号：US17365213
申请日：2021-07-01
申请人： Pfizer Inc.
发明人： Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Martin Youngjin Pettersson , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
摘要： The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
-
公开(公告)号：US20240238425A1
公开(公告)日：2024-07-18
申请号：US18541015
申请日：2023-12-15
申请人： Pfizer Inc.
发明人： Jan Antoinette Cusi Romero Adams , Yotam Ashkenazi , Matthew Frank Brown , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Yajing Lian , Deane Milford Nason, II , Steven Victor O'Neil , Amanda Brooke Pecora , Alistair Dean Richardson , Matthew Forrest Sammons , Yang Wang , Ann Sorrentino Wright , Jun Xiao , Lei Zhang , Liying Zhang
摘要： Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
公开(公告)号：US20230120707A1
公开(公告)日：2023-04-20
申请号：US17906132
申请日：2021-03-31
申请人： Pfizer Inc.
发明人： Robert Steven Kania , Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Forrest Sammons , Jamison Bryce Tuttle
IPC分类号： C07D403/14 , A61K9/20 , A61K9/00
摘要： The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound
-
公开(公告)号：US11351149B2
公开(公告)日：2022-06-07
申请号：US17395139
申请日：2021-08-05
申请人： Pfizer Inc.
发明人： Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC分类号： C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427
摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号：US11926642B2
公开(公告)日：2024-03-12
申请号：US17365213
申请日：2021-07-01
申请人： Pfizer Inc.
发明人： Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
CPC分类号： C07F9/5728 , A61P31/14 , C07B2200/13
摘要： The invention relates to compounds of formula I
wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.-
公开(公告)号：US20230339930A1
公开(公告)日：2023-10-26
申请号：US18004996
申请日：2021-07-07
申请人： Pfizer Inc.
发明人： Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Qingyi Yang
IPC分类号： C07D417/14 , A61P31/14
CPC分类号： C07D417/14 , A61P31/14
摘要： The invention relates to compounds of Formula I
wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.015 秒)
